author-photo

Amy Pace

Alexion Pharmaceuticals

4

Papers

270

Citations

Citation Trend

Filter By

Papers (2) Sort By

Journal Conference Others

Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: subgroup analyses of the randomized controlled phase 3 PREVENT trial

2021 Multiple sclerosis and related disorders
Show All
- Source
- Cite
- Save
Citations (5)
Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from the Phase 3 PREVENT Study (1788)

2020 Neurology
Show All
- Source
- Cite
- Save
Citations (1)